Medical Devices · NYSE: BDX
Becton Dickinson earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends September · next results expected around 8 Feb 2027
Latest: Q4 FY2026
BD signed a U.S. government manufacturing partnership with $19 billion of planned investment and Section 232 tariff relief, while launching new vascular and tissue-regeneration products as New BD.
BD finished its transformation into a four-segment MedTech company after spinning off its Biosciences and Diagnostic Solutions business into Waters in February. Growth was led by Advanced Patient Monitoring, PureWick, Advanced Tissue Regeneration, biologic drug delivery and BD Rowa. Interventional grew fastest of the four segments. Connected Care lagged as Alaris infusion pump capital sales fell. BD also won U.S. launch clearance for new vascular and hernia products.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 FY24 | $5.4B * |
| Q1 FY25 | $5.2B |
| Q2 FY25 | $4.5B |
| Q3 FY25 | $4.7B |
| Q4 FY25 | $8.3B * |
| Q1 FY26 | $5.3B |
| Q2 FY26 | $4.7B |
| Q3 FY26 | $5.0B |
Data
| Q1 FY25 | $1.04 |
| Q2 FY25 | $1.07 |
| Q3 FY25 | $2.00 |
| Q1 FY26 | $1.34 |
| Q2 FY26 | -$1.11 |
| Q3 FY26 | $1.37 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 FY24 | 11.4% |
| Q1 FY25 | 8.8% |
| Q2 FY25 | 8.5% |
| Q3 FY25 | 15.6% |
| Q4 FY25 | 14.1% |
| Q1 FY26 | 10.5% |
| Q2 FY26 | 2.0% |
| Q3 FY26 | 13.3% |
Data
| Q1 FY25 | $588.0M |
| Q1 FY26 | $549.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.4Bd | $5.2B | $4.5B | $4.7B | $8.3Bd | $5.3B | $4.7B | $5.0B |
| Operating income | $622.0Md | $453.0M | $383.0M | $739.0M | $1.2Bd | $552.0M | $93.0M | $663.0M |
| Operating margin | 11.4% | 8.8% | 8.5% | 15.6% | 14.1% | 10.5% | 2.0% | 13.3% |
| Net income | $400.0Md | $303.0M | $308.0M | $574.0M | $493.0Md | $382.0M | -$311.0M | $377.0M |
| Diluted EPS | — | $1.04 | $1.07 | $2.00 | — | $1.34 | -$1.11 | $1.37 |
| Operating cash flow | — | $693.0M | — | — | — | $657.0M | — | — |
| Capital expenditure | $296.0Md | $105.0M | $114.0Md | $164.0Md | $377.0Md | $108.0M | $125.0Md | $143.0Md |
| Free cash flow | — | $588.0M | — | — | — | $549.0M | — | — |
| R&D expense | $302.0Md | $343.0M | $232.0M | $230.0M | $559.0Md | $306.0M | $249.0M | $258.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 6 Aug 202610-Q for the period ended 30 Jun 2026SEC ↗
- 7 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 9 Feb 202610-Q for the period ended 31 Dec 2025SEC ↗
- 25 Nov 202510-K for the period ended 30 Sep 2025SEC ↗
- 7 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 1 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 6 Feb 202510-Q for the period ended 31 Dec 2024SEC ↗
- 27 Nov 202410-K for the period ended 30 Sep 2024SEC ↗